Profile: Cambrex Corporation (CBM)

Cambrex Corporation (Cambrex) is a life sciences company that provides products and services worldwide to pharmaceutical and generic drug companies. The Company's products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates produced under the United States Food and Drug Administration (FDA) current Good Manufacturing Practices (cGMP) for use in the production of prescription and over-the-counter drug products and other fine custom chemicals derived from organic chemistry. In January 2008, Cambrex acquired AS ProSyntest, an API research and development company.

Cambrex has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment. The Company's business is primarily consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Products and services are sold to a diverse group of more than 500 customers, with two customers individually accounting for more than 10% of 2008 sales, one, a pharmaceutical company with which a long-term sales contract is in effect, accounted for 10%. A second customer, a distributor representing multiple customers, accounted for 11.8%. The Company's products are sold through a combination of direct sales and independent agents.